# Monitoring the IMmUological TOXicity of Drugs

> **NCT03480529** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 662 (actual)

## Conditions studied

- Arthritis
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Capillary Leak Syndrome
- Hepatitis

## Interventions

- **DRUG:** drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom

## Key facts

- **NCT ID:** NCT03480529
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2018-03-10
- **Final completion:** 2018-03-10
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480529, "Monitoring the IMmUological TOXicity of Drugs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03480529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*